Serum Vitamin D Levels in Persons with Type 2 Diabetes Mellitus in Lagos, Nigeria

Anyanwu AC1*, Olopade OB2, Onung SI3, Odeniyi IA2, Coker HAB4, Fasanmade OA2 and Ohwovoriole AE2

1Endocrinology Unit, Department of Internal Medicine, Federal Medical Centre, Owerri, Nigeria
2Endocrinology Unit, College of Medicine University of Lagos, Lagos University Teaching Hospital, Nigeria
3Endocrinology Unit, University of Uyo Teaching Hospital, Uyo, Nigeria
4Faculty of Pharmaceutical Sciences, College of Medicine University of Lagos, Nigeria

*Corresponding author: Dr. Anyanwu AC, Endocrinology Unit, Department of Internal Medicine, Federal Medical Centre, Owerri, Imo State, Nigeria

Abstract

The prevalence of Type 2 diabetes mellitus (T2DM) continues to climb in many parts of the globe in association with the rise in Obesity. In parallel to the increase in the prevalence of diabetes mellitus, evidence indicates a high prevalence of vitamin D deficiency Worldwide. Areas with high prevalence of vitamin D insufficiency and deficiency have been associated with a higher prevalence of diabetes. The reported prevalence of vitamin D deficiency among subjects with Type 2 diabetes mellitus ranges from 63.5% to 91.1%.

Most studies on vitamin D status among Diabetes mellitus subjects involved Caucasians. Data on this subject matter is scarce in Africa.

Materials and methods: This study was conducted between the months of May and August (Rainy/winter season) at the Diabetes clinic of the Lagos University Teaching Hospital, LUTH, Lagos, Nigeria. It was an analytical cross-sectional study. A total of 114 eligible type 2 diabetes mellitus participants and 60 healthy controls participated. All participants were clinically assessed and blood samples for relevant investigations taken. Serum vitamin D level was analyzed using the High Performance Liquid Chromatography (HPLC) method.

Results: The mean age was 52 ± 7.6 years in the T2DM group and 50 ± 8.4 in the control group, (p = 0.9). The female to male ratio in both T2DM and healthy control subjects was 1.5:1.

Majority of the study subjects had vitamin D deficiency with prevalence of 72 (63.2%) in T2DM subjects and 32 (53.3%) in the controls (p = NS). There was no significant difference in the distribution of Vitamin D3 deficiency status by age or sex in both T2DM and Control groups.

The mean serum vitamin D level in T2DM subjects with vitamin D deficiency was 9.2 ± 1.1 ng/dl and 21.5 ± 8.7 ng/dl in the sufficient group (t = 11.9, p = 0.0001). The mean HbA1c and Fasting plasma glucose were higher in the vitamin D deficient group compared to the sufficient group (7.5 ± 1.9% and 148 ± 60.9 mg/dl vs. 6.8 ± 1.6% and 134 ± 43.5 mg/dl respectively, p NS). The proportion of subjects with good glycaemic control (HbA1C < 7.0%) was significantly higher in the vitamin D sufficient group 19 (73.1%) compared to the vitamin D deficient group, 33 (45.8%), Z = -2.39, p = 0.01).

Conclusion: Vitamin D deficiency is common among the participants in this study. This alludes to the widespread vitamin D deficiency and insufficiency in both apparently healthy populations and patients with various pathologies including diabetes mellitus. The season of study (rainy/winter) may have contributed to the low levels of vitamin D among the participants.

Keyword

Vitamin D deficiency, Type 2 diabetes, Serum calcium

Introduction

The prevalence of Type 2 diabetes mellitus (T2DM) continues to climb in many parts of the globe in association with the rise in Obesity [1]. Currently, there are 415
million people worldwide living with diabetes and 90-95% have T2DM. This number is expected to reach 642 million by 2040 [2]. Available data have shown that Nigeria presents with the largest number of persons with diabetes mellitus in Africa and report indicates that the prevalence of Type 2 DM in Nigeria is about 4-5% [3].

A novel association with diabetes mellitus that has received considerable attention recently is Vitamin D deficiency. Vitamin D deficiency is usually caused by low dietary vitamin D intake and reduced cutaneous production of vitamin D. The latter condition is associated with reduced sunlight exposure due to geographic location, genetic background affecting skin colour, age, and cultural or religious practices [1].

In the skin, 7-dehydrocholesterol, a derivative of cholesterol is photolysed by ultraviolet light at wavelengths between 270 and 300 nm, with peak synthesis occurring between 295 and 297 nm [4]. The products are pre-vitamin D₃ (preD₃), lumisterol and tachysterol. At room temperature, the transformation of pre-vitamin D₃ to vitamin D₃ takes about 12 days to complete [5].

Melanin in the epidermis, by absorbing UV irradiation, can reduce the effectiveness of sunlight in producing vitamin D₃ in the skin. Persons with darker skin tones, such as Africans and south Asians, exhibit lower serum concentrations of vitamin D, due to reduced skin absorption of ultraviolet B light by darker skin pigments [6-8].

The seasonal variation of vitamin D levels can be quite pronounced with higher levels during the summer months and lower levels during the winter. The extent of this seasonal variation depends on the latitude, and thus the intensity of sun light striking the exposed skin [7]. Serum vitamin D levels are frequently lower during winter months due to reduced exposure to sun light, this may be one important reason for the lower serum vitamin D levels, in Blacks and Hispanics living in temperate latitudes [6].

Consistent with the hypothesis that vitamin D deficiency and diabetes are related, areas with high prevalence of vitamin D insufficiency and deficiency have been associated with a higher prevalence of diabetes [5]. The reported prevalence of vitamin D deficiency among subjects with Type 2 diabetes mellitus ranges from 63.5% to 91.1% [6,7].

Hypovitaminosis D has recently emerged as one of the factors contributing to the development of both type 1 and type 2 diabetes mellitus [9-15].

The effect of vitamin D on B-cell function and insulin sensitivity has been observed in both animal and human studies [8]. Vitamin D is required for and improves the production of insulin; and also improves insulin sensitivity [16]. Vitamin D facilitates the biosynthetic capacity of B-cell and also accelerates the conversion of pro-insulin to insulin [17].

Most published work on vitamin D status in Nigeria/sub-Saharan Africa was done among children aged between 6 months and 8 years, and a few on healthy pregnant and non-pregnant women [18-21].

Glew, et al. in his work on vitamin D status in adult Fulani men and women (non-diabetes mellitus subjects) in Gombe State Nigeria, reported a high prevalence of hypovitaminosis D in both men and women with values of 45% and 83% respectively [20].

In Nigeria, there are no available data on the vitamin D status of diabetes mellitus subjects. This study aims to evaluate the serum vitamin D status of T2DM subjects in Lagos. The primary objective (outcome) is to determine and compare the prevalence of vitamin D deficiency in T2DM and control subjects. While the secondary objective is to compare glycemic control (HbA1c) in vitamin D sufficient and deficient T2DM subjects.

Materials and Methods

This study was conducted between the months of May and October (Rainy/winter season) at the Diabetes clinic of the Lagos University Teaching Hospital, LUTH, Lagos, Nigeria. It was an analytical cross-sectional study. Eligible type 2 diabetes mellitus participants were selected from the LUTH diabetes Clinic register, and invited to the Endocrinology laboratory of Medicine Department. Healthy control participants who volunteered, and met the inclusion criteria were selected among LUTH staff members and the General Out-Patient Department, GOPD, and given appointment to participate. Participants were instructed to report between 08:00 a.m and 10:00 a.m (after an overnight fast of 8 to 12 hours) on the appointment date. All participants were clinically assessed and blood samples for relevant investigations taken.

The study participants were recruited into the study after signing the informed consent form indicating free willingness to participate in the study. The study was done at no financial cost to the study participants. Approval for the study was obtained from the Health and Ethics Committee of LUTH. Participants were free to withdraw from the study at any stage if they so wished. No participant was to be penalized in any way for deciding to opt out of the study.

Inclusion and exclusion criteria for the study participants

Inclusion criteria: The following groups of persons were eligible for recruitment into the study:

A) Type 2 diabetes mellitus participants
- Participants aged 35 to 65 years with type 2 diabetes mellitus and on oral antidiabetics
- Participants who gave informed consent

B) Control participants

• Participants who gave informed consent

Inclusion and exclusion criteria for the study participants

Inclusion criteria: The following groups of persons were eligible for recruitment into the study:

A) Type 2 diabetes mellitus participants
- Participants aged 35 to 65 years with type 2 diabetes mellitus and on oral antidiabetics
- Participants who gave informed consent

B) Control participants

• Participants who gave informed consent

Inclusion and exclusion criteria for the study participants

Inclusion criteria: The following groups of persons were eligible for recruitment into the study:

A) Type 2 diabetes mellitus participants
- Participants aged 35 to 65 years with type 2 diabetes mellitus and on oral antidiabetics
- Participants who gave informed consent

B) Control participants

• Participants who gave informed consent
• Apparently healthy participants aged 35 to 65 years who gave informed consent (matched for age and sex)

**Exclusion criteria:** Those who were excluded from the study were:

• Participants below 35 years or above 65 years
• Participants with type 1 DM
• Type 2 DM participants on insulin (due to influence of insulin antibodies on serum insulin assay)
• Pregnant women (serum vitamin D levels are generally low in pregnancy)
• Participants with chronic diseases including renal insufficiency (GFR < 30 ml/min), history of chronic liver disease or ALT > 5 times upper reference limit, tuberculosis, diarrheal or malabsorption state.
• Patients on vitamin D supplements or drugs that affect vitamin D metabolism such as corticosteroids.

**Sample size calculation**

The sample size was calculated using the Kish and Leslie formula.

\[
N = \frac{Z^2pq}{d^2}
\]

Where,

- \(N\) = desired sample size.
- \(Z\) = Standard deviation set at 1.96 corresponding to 95% confidence interval.
- \(P\) = Prevalence of Vitamin D deficiency = 91.1%
- \(q\) = 1.0 – \(P\)
- \(d\) = degree of accuracy required set at 0.05 (5%)

\[
N = \frac{(1.96)^2 \times 0.911 \times (1 - 0.911)}{(0.05)^2}
\]

\[
= \frac{3.842 \times 0.08 \times 0.911}{0.0025}
\]

= 112

Control Participants: The ratio of the controls to T2DM participants was 1:2. Hence the estimated number of control participants was 56.

The total calculated sample size was 168 (112 T2DM and 56 control participants). To allow for a dropout rate of about 10%, 184 subjects were estimated to be recruited for this study (T2DM participants = 122; and controls = 62).

**Laboratory procedures**

In a fasting state, between 08.00 a.m. and 10.00 a.m., 10 ml of venous blood was collected from the antecubital fossa of each subject. Tourniquet was lightly applied about 2 to 4 cm above puncture site and left for less than 2 minutes. The blood sample collected was shared into appropriate sample bottles for the relevant tests as stated below.

**Assay of serum vitamin D**

Three milliliters of blood sample were collected into plain bottles. The samples were left for 15 to 20 minutes to clot at room temperature and then centrifuged at a speed of 3000 r.p.m for 10 minutes to obtain the serum which was stored at -80 °C (in ultralow freezer) until when used.

The Agilent series 1120 HPLC system with quaternary pump was employed for the assay. Prior deproteinization of the serum was done by liquid phase extraction using acetonitrile. The extracted sample was transferred to an auto sample vial and 20 µL injected into the HPLC system. Separation was performed on a Zorbax eclipse XDB-C8 column (4.6 × 150 mm, 5 µm size) maintained at 40 °C. The mobile phase was methanol/acetonitrile (15:85) and the flow rate was 1 ml/min. Detection was at 280 nm, the injection volume was 20 µL. The vitamin D3 peaks were resolved with retention time of 4.6 to 4.8 mins.

**Calibration curve of vitamin D3 in serum**

Figure 1 shows the calibration curve for the determination of serum Vitamin D3. Samples were run in duplicates and the mean absorbance plotted against concentrations of vitamin D3. The calibration curve was linear in the range of serum vitamin D3 concentrations (10-80 ng/ml) of interest. Using this curve the vitamin D3 concentrations of patients were obtained by interpolation.

**Accuracy of vitamin D3 assay**

Various concentration of vitamin D3 (10, 60 and 80 ng/ml) were added to three different aliquots of same serum. Each sample concentration was injected and run three times and the average taken. The serum used for the process had undetectable vitamin D3 level; hence the baseline vitamin D3 level was assumed as zero. The recovery study showed that the method employed was efficient and accurate in recovering the fat soluble vitamin D3 from serum samples; the recovery rate ranged from 91.3 to 116.7%, with a mean of 104.4 ± 12.7%.

**Plasma glucose assay**

About 2 ml of blood was transferred into fluoride oxalate bottles. The sample was then centrifuged at a speed of 3000 r.p.m for 10 min. The plasma was separated and stored at -20 °C until the time for analysis. The Trinder (Glucose-oxidase) method was employed [22]. The process involved the addition of 2 ml of plasma into about 2 ml of a glucose oxidase containing solution in a test-tube. The mixture was incubated at room temperature for 15 minutes; it was then allowed to cool to room temperature during which time the colour changes from
Statistical analysis was done using the Statistical Package for Social Sciences, SPSS version 17. Data distribution (normality) was investigated using the D’Agostino-Pearson Omnibus normality test for appropriate statistical analysis. Summary description of data was listed as mean, median, standard deviations, confidence intervals, proportions and tables.

Data on serum vitamin D₃ levels were not normally distributed; hence the reference values were derived from the anti-log of the log transformed data. Comparisons of the clinical, anthropometric and biochemical variables were analysed using student’s T-test. Comparisons of categorical variables were analysed using Chi-square test. P-values less than 0.05 were considered statistically significant.

Results

Participants flow

A total of 194 participants (124 type 2 diabetes mellitus and 70 healthy control subjects) were invited to participate in this study. Of the 70 control participants, 10 did not meet the inclusion criteria (four had hypertension, three had elevated fasting glucose in the diabetic range, one was on treatment for pulmonary tuberculosis and two were pregnant). Out of the 124 T2DM patients invited, 10 were excluded (8 did not meet inclusion criteria while 2 declined).

The mean age was 52 ± 7.6 years in the T2DM group.
and 50 ± 8.4 in the control group, (p = 0.9). The female to male ratio in both T2DM and healthy control subjects was 1.5: 1. The mean body mass index, BMI, was 27.2 ± 4.6 and 27.2 ± 5.1 in the T2DM and control groups respectively, (p = 0.76).

**Serum vitamin D status of study participants**

Comparison of vitamin D status of type 2 diabetes and control participants: Table 1 shows the distribution of participants by vitamin D status. Reference values for serum vitamin D were derived from the 95% confidence interval of anti-log of the transformed control group data. The serum vitamin D levels were then classified as shown in the Table 1. Majority of the study subjects had vitamin D deficiency with prevalence of 72 (63.2%) in T2DM subjects and 32 (53.3%) in the controls. This difference between the groups was not statistically significant (χ² = 1.62, p = 0.44).

**Comparison of biochemical variables in vitamin D deficient and sufficient T2DM subjects**

The proportion of T2DM subjects with good glycemic control (HbA1C ≤ 7.0%) was significantly higher in the vitamin D sufficient group 19 (73.1%) compared to the vitamin D deficient group, 33 (45.8%), Z = -2.39, p = 0.01. Comparisons of other biochemical variables are as shown in Table 3.

The mean age was 52 ± 7.6 years in the T2DM group and 50 ± 8.4 in the control group, (p = 0.9). The female to male ratio in both T2DM and healthy control subjects was 3:2.

Majority of the study subjects had vitamin D deficiency with prevalence of 72 (63.2%) in T2DM subjects and 32 (53.3%) in the controls. This difference between the groups was not statistically significant (χ² = 1.62, p = 0.44).

**Table 1: Distribution of Study Participants by Serum Vitamin D Status.**

| Vitamin D status       | T2DM      | Controls  | χ²  | P value |
|------------------------|-----------|-----------|-----|---------|
| Vit. D deficiency†     | 72 (63.2) | 32 (53.3) | 1.62| 0.44    |
| Vit. D Insufficiency²  | 16 (14)   | 10 (16.7) |     |         |
| Optimal Vit. D³        | 26 (22.8) | 18 (30)   |     |         |
| Total                  | 114 (100) | 60 (100)  |     |         |

Values are expressed as n (%). †(< 11.1 ng/ml); ‡(11.1 to 13.3 ng/ml); and †(> 13.3 ng/ml).

**Table 2: Distribution of vitamin D deficient Participants by Age and Sex.**

| Age (years) | T2DM      | Controls  | χ²  | p-value |
|-------------|-----------|-----------|-----|---------|
| 35-45       | 17 (23.6) | 10 (31.25)| 0.75| 0.68    |
| 46-55       | 28 (38.9) | 12 (37.5) |     |         |
| 56-65       | 27 (37.5) | 10 (31.25)|     |         |
| Total       | 72 (100)  | 32 (100)  |     |         |

**Table 3: Biochemical variables in vitamin D deficient and vitamin D sufficient T2DM subjects.**

| Variables          | Vitamin D Sufficient T2DM (n = 26) | Vitamin D Deficient T2DM (n = 72) | T - value | P - value |
|--------------------|------------------------------------|------------------------------------|-----------|-----------|
| FPG (mg/dl)        | 134 ± 43.5                         | 148 ± 60.9                         | 1.05      | 0.29      |
| Serum calcium (mmol/L) | 2.24 ± 0.1                      | 2.23 ± 0.1                         | 0.43      | 0.66      |
| Vit D3 (ng/dl)     | 21.5 ± 8.7                         | 9.1 ± 1.1                          | 11.9      | 0.0001    |
| IR                 | 6.35 ± 5.6                         | 6.9 ± 6.1                          | 0.46      | 0.64      |
| HOMA-B (%)         | 122 ± 93.3                         | 118 ± 96.4                         | 0.15      | 0.88      |
| HbA1c (%)          | 6.8 ± 1.6                          | 7.5 ± 1.9                          | 1.63      | 0.1       |

Values expressed as mean ± SD; FPG: Fasting plasma glucose; IR: Insulin resistance; HOMA-B: Homeostasis method for assessment of Beta cell function.
significant difference in the distribution of Vitamin D$_3$ deficiency status by age or sex in both T2DM and Control groups.

Majority of the study participants, 100 (90.4%) of T2DM patients and 59 (98.3%) of the healthy controls had normal serum calcium level (2.1 to 2.55 mmol/L). Asymptomatic hypocalcaemia (serum calcium < 2.1 mmol/l) was seen in 11 (9.6%) of T2DM patients and none in the control group. Mean corrected serum calcium level was significantly lower in T2DM subjects compared to controls (2.23 ± 0.09 mmol/l vs. 2.28 ± 0.09 mmol/l respectively, p=0.003).

The mean serum vitamin D level in T2DM subjects with vitamin D deficiency was 9.2 ± 1.1 ng/dl and 21.5 ± 0.7 ng/dl in the sufficient group (t = 11.9, p = 0.0001). The mean HbA1c and Fasting plasma glucose were higher in the vitamin D deficient group compared to the sufficient group (7.5 ± 1.9% and 148 ± 60.9 mg/dl vs. 6.8 ± 1.6% and 134 ± 43.5 mg/dl respectively, p<0.003).

The findings from this study, to a large extent corroborated with previous work in this field. The prevalence of vitamin D deficiency in this study is 63.2% and 53.3% in T2DM and controls respectively. This alludes to the widespread vitamin D deficiency and insufficiency in both apparently healthy populations and patients with various pathologies including diabetes mellitus [24]. The reported prevalence of vitamin D deficiency among persons with Type 2 diabetes mellitus ranges from 63.5% to 91.1% [6,7]. The reason for this high prevalence of vitamin D deficiency among the study participants is not clear. However, the season (rainy/winter) during which the study was carried out may play a role, as the exposure to sunlight and therefore vitamin D production is expected to be low during the period. There are several reports on seasonal variation of serum vitamin D and glycaemia [25-27]. The higher levels of HbA1c and Fasting plasma glucose in vitamin D deficient T2DM participants compared with their vitamin D sufficient counterpart is consistent with the inverse relationship between vitamin D levels and glycaemic control reported in other similar studies [12,28-30].

The finding of a lower mean serum calcium concentration in persons with T2DM compared to healthy control is consistent with those of other studies and may be due to the reported elevated urinary excretion of calcium in T2DM [31]. The finding of a predominantly normal calcium levels among the study participants vis-a-vis the extent of vitamin D deficiency status is as reported by Sedrani who found vitamin D deficiency in about 50% of his study participants and all had a normal serum calcium level [32]. The reason for this is not clear, but it may have something to do with the threshold for vitamin D level below which derangement of serum calcium may occur. The serum vitamin D levels observed in this study, though low, may be enough to maintain calcium levels within normal range, coupled with intake of calcium containing supplements or milk among the participants.

**Conclusion**

Vitamin D deficiency is common among the participants in this study. This alludes to the widespread vitamin D deficiency and insufficiency in both apparently healthy populations and patients with various pathologies including diabetes mellitus. The season of study (rainy/winter season) may have contributed to the low levels of vitamin D among the participants.

**References**

1. Maxwell CS, Wood RJ (2011) Update on vitamin D and Type 2 diabetes. Nutr Rev 69: 291-295.
2. Shaw J, Sicree R, Zimmet P (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clinical Pract 87: 4-14.
3. International Diabetes Federation (2019) Global Burden. Epidemiology and Morbidity. Diabetes and Impaired Glucose Tolerance. Diabetes Atlas.
4. Holick MF (1995) Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 61: 638S-645S.
5. Holick MF (2004) Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease and osteoporosis. Am J Clin Nutr 79: 362-371.
6. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW (2004) Genetic evidence that the human CYP2RI enzyme is a key vitamin D 25-Hydroxylase. Proc Natl Acad Sci U S A 101: 7711-7715.
7. Bell NH, Greene A, Epstein S, Oexmann J, Shaw S, et al. (1985) Evidence for alteration of vitamin D-endocrine system in Blacks. J Clin Invest 76: 470-473.
8. Webb AR, Kline L, Holick MF (1988) Influence of season and latitude on the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 67: 373-378.
9. Mattila C, Knekt P, Mannisto S, Rissanen H, Laaksonen MA, et al. (2007) Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 30: 2569-2570.
10. Dalgaard C, Petersen MS, Weihe P, Grandjean P (2011) Vitamin D status in relation to glucose metabolism and type 2 diabetes in septuagenarians. Diabetes Care 34: 1284-1288.
11. Pietschmann P, Scherthanher G, Woloszczuk W (1988) Serum osteocalcin levels in diabetes mellitus: Analysis of the type of diabetes and microvascular complications. Diabetologia 31: 892-895.
12. Chertow BS, Sivitz WI, Baranetsky NG, Clarke SA, Waite A, et al. (1983) Cellular mechanisms of insulin release: The effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 113: 1511-1518.
13. Ken CC, Audrey C, Vay Liang WG, Mohammed FS (2004) Hypovitaminosis D is associated with insulin resistance and B-cell dysfunction. Am J Clin Nutr 75: 820-825.
14. Bourlon PM, Faure-Dussert A, Billaudel B (1999) The de novo synthesis of numerous proteins is decreased during vitamin D3 deficiency and is gradually restored by 1,25-dihydroxyvitamin D3 repletion in the islet of Langerhans of rat. J Endocrinol 162: 101-109.

15. Wang L, Manson JE, Song Y, Sesso HD (2010) Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 152: 315-323.

16. Lips P (2007) Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol 103: 620-625.

17. Gannage-Yared MH, Chemali R, Yaacoub N, Halaby G (2000) Hypovitaminosis D in a sunny country: Relation to lifestyle and bone markers. J Bone Miner Res 15: 1856-1862.

18. Okonofua F, Houlders S, Bell J, Dandonia P (1986) Vitamin D nutrition in pregnant Nigerian women at term and their newborn infants. J Clin Pathol 39: 650-653.

19. Oduwole AO (2002) Vitamin D nutrition in Nigerian children with pneumonia. In: Thacher TD, Nutritional rickets in Nigerian children: The way forward. Nestle Nutrition, Vevey, Switzerland, 39-43.

20. Glew RH, Crosse MY, Polanams J, Okolie HI, Vanderjagt DJ (2010) Vitamin D status of semi nomadic Fulani men and women. J Natl Med Assoc 102: 485-490.

21. Prentice A, Schoemaker I, Jones SK, Jarjou AM, Goldberg GR (2009) Vitamin D deficiency and its health consequences in Africa. Clin Rev Bone Miner Metab 7: 94-106.

22. Marks V (1996) An improved glucose oxidase method for determining blood, CSF, urine glucose levels. Clin Chim Acta 251: 19-24.

23. Fluckiger R, Woodtl T, Berger W (1984) Quantitation of glycosylated hemoglobin by boronate affinity chromatography. Diabetes 33: 73-76.

24. Vieth R, Cole DE, Hawker GA, Trang HM, Rubin LA (2001) Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 55: 1091-1097.

25. Khaled El Baba, Mira S Zantout, Randa Akel, Sami T Azar (2011) Seasonal variation of vitamin D and HbA1c levels in patients with type 1 diabetes mellitus in the middle East. Int J Gen Med 4: 635-638.

26. Mark J Bolland, Andrew B Grey, Ruth W Ames, Barbara H Mason, Anne M Horne, et al. (2007) The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr 86: 959-964.

27. Matthew Smith (2010) Seasonal, ethnic and gender variations in serum vitamin D3 levels in the local population of Peterborough. The International Journal of Student Research 3: 124-131.

28. Kositawat J, Freeman VL, Gerber BS, Geraci S (2010) Association of A1C levels with vitamin D status in U.S adults: Data from the National Health and Nutrition Examination Survey. Diabetes Care 33: 1236-1238.

29. Yu JR, Lee SA, Lee JG, Seong GM, Ko SJ, et al. (2012) Serum vitamin D status and its relationship to metabolic parameters in patients with type 2 diabetes mellitus. Chonnam Med J 48: 108-115.

30. Anyanwu AC, Fasanmade OA, Coker HAB, Ohwovoriole AE (2017) Relationship between vitamin D levels and glycaemic control in type 2 diabetes mellitus patients in Lagos, Nigeria. J Diabetol 8: 32-36.

31. Blasiak M, Kuska J, Kokot F, Iryniec T (1989) Selected indicators of calcium-phosphate metabolism in patients with diabetes mellitus. Endokrynol Pol 40: 251-262.

32. Sedrani SH (1998) Low 25-hydroxyvitamin D and normal serum calcium concentration in Saudi Arabia: Riyadh region. Ann Nutr Metab 28: 181-185.